G1G.F Zelira Therapeutics Limited

Healthcare Biotechnology Frankfurt Exchange
0.3000 EUR
Close of Nov 12, 2026
0.1670 0.5100
Market cap
EUR 3.94M
P/E
-
P/B
0.32x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is G1G.F undervalued?

Graham number

The Graham number of Zelira Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zelira Therapeutics Limited fundamental analysis

No fundamental analysis for Zelira Therapeutics Limited yet.

Zelira Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zelira Therapeutics Limited

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, i…

Full company profile